Enanta Pharmaceuticals (ENTA)
Market Price (2/3/2026): $13.18 | Market Cap: $281.8 MilSector: Health Care | Industry: Biotechnology
Enanta Pharmaceuticals (ENTA)
Market Price (2/3/2026): $13.18Market Cap: $281.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% | Weak multi-year price returns2Y Excs Rtn is -36%, 3Y Excs Rtn is -146% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -85 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -131% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Stock price has recently run up significantly12M Rtn12 month market price return is 158% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -8.7% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 28% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -49% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33% | ||
| High stock price volatilityVol 12M is 117% | ||
| Key risksENTA key risks include [1] the recent clinical trial failure of its lead RSV candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -36%, 3Y Excs Rtn is -146% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -85 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -131% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 158% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -8.7% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 28% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -49% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33% |
| High stock price volatilityVol 12M is 117% |
| Key risksENTA key risks include [1] the recent clinical trial failure of its lead RSV candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) stock has gained about 20% since 10/31/2025 because of the following key factors:
1. Enanta Pharmaceuticals exceeded Q4 2025 earnings per share estimates. The company reported a loss of $0.87 per share, outperforming the consensus estimate of a $1.13 loss. This positive earnings surprise, despite a revenue miss, was attributed to improved profitability stemming from cost-cutting measures and increased royalties from AbbVie's hepatitis C treatment.
2. The company significantly strengthened its financial position. In October 2025, Enanta Pharmaceuticals successfully closed a public offering that generated $74.75 million in gross proceeds. This offering bolstered its cash reserves to $216.7 million as of December 31, 2024, extending its projected operational runway into fiscal year 2029.
Show more
1. Enanta Pharmaceuticals exceeded Q4 2025 earnings per share estimates. The company reported a loss of $0.87 per share, outperforming the consensus estimate of a $1.13 loss. This positive earnings surprise, despite a revenue miss, was attributed to improved profitability stemming from cost-cutting measures and increased royalties from AbbVie's hepatitis C treatment.
2. The company significantly strengthened its financial position. In October 2025, Enanta Pharmaceuticals successfully closed a public offering that generated $74.75 million in gross proceeds. This offering bolstered its cash reserves to $216.7 million as of December 31, 2024, extending its projected operational runway into fiscal year 2029.
Show more
Stock Movement Drivers
Fundamental Drivers
The 20.3% change in ENTA stock from 10/31/2025 to 2/2/2026 was primarily driven by a 19.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.96 | 13.19 | 20.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 65 | 65 | 0.8% |
| P/S Multiple | 3.6 | 4.3 | 19.4% |
| Shares Outstanding (Mil) | 21 | 21 | 0.0% |
| Cumulative Contribution | 20.3% |
Market Drivers
10/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| ENTA | 20.3% | |
| Market (SPY) | 2.0% | 21.6% |
| Sector (XLV) | 7.9% | 23.4% |
Fundamental Drivers
The 74.0% change in ENTA stock from 7/31/2025 to 2/2/2026 was primarily driven by a 71.9% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.58 | 13.19 | 74.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 64 | 65 | 1.3% |
| P/S Multiple | 2.5 | 4.3 | 71.9% |
| Shares Outstanding (Mil) | 21 | 21 | -0.1% |
| Cumulative Contribution | 74.0% |
Market Drivers
7/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| ENTA | 74.0% | |
| Market (SPY) | 10.3% | 9.4% |
| Sector (XLV) | 19.9% | 3.1% |
Fundamental Drivers
The 158.1% change in ENTA stock from 1/31/2025 to 2/2/2026 was primarily driven by a 169.6% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.11 | 13.19 | 158.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 68 | 65 | -3.4% |
| P/S Multiple | 1.6 | 4.3 | 169.6% |
| Shares Outstanding (Mil) | 21 | 21 | -0.9% |
| Cumulative Contribution | 158.1% |
Market Drivers
1/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| ENTA | 158.1% | |
| Market (SPY) | 16.6% | 14.9% |
| Sector (XLV) | 7.4% | 14.1% |
Fundamental Drivers
The -75.3% change in ENTA stock from 1/31/2023 to 2/2/2026 was primarily driven by a -66.4% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 53.38 | 13.19 | -75.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 86 | 65 | -24.2% |
| P/S Multiple | 12.9 | 4.3 | -66.4% |
| Shares Outstanding (Mil) | 21 | 21 | -2.9% |
| Cumulative Contribution | -75.3% |
Market Drivers
1/31/2023 to 2/2/2026| Return | Correlation | |
|---|---|---|
| ENTA | -75.3% | |
| Market (SPY) | 77.5% | 18.2% |
| Sector (XLV) | 22.2% | 20.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ENTA Return | 78% | -38% | -80% | -39% | 174% | -18% | -69% |
| Peers Return | 7% | -14% | -9% | -9% | 89% | 7% | 53% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| ENTA Win Rate | 50% | 50% | 25% | 50% | 67% | 0% | |
| Peers Win Rate | 45% | 43% | 42% | 42% | 65% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ENTA Max Drawdown | -3% | -49% | -82% | -39% | -26% | -21% | |
| Peers Max Drawdown | -22% | -38% | -34% | -28% | -26% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GILD, VIR, ARWR, ABUS, IONS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/2/2026 (YTD)
How Low Can It Go
| Event | ENTA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -91.6% | -25.4% |
| % Gain to Breakeven | 1090.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -35.1% | -33.9% |
| % Gain to Breakeven | 54.2% | 51.3% |
| Time to Breakeven | 568 days | 148 days |
| 2018 Correction | ||
| % Loss | -54.1% | -19.8% |
| % Gain to Breakeven | 118.1% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to GILD, VIR, ARWR, ABUS, IONS
In The Past
Enanta Pharmaceuticals's stock fell -91.6% during the 2022 Inflation Shock from a high on 11/5/2021. A -91.6% loss requires a 1090.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
AI Analysis | Feedback
```htmlHere are 1-3 brief analogies for Enanta Pharmaceuticals (ENTA):
- A discovery-focused Gilead Sciences for new small molecule antiviral treatments.
- A small molecule Vertex Pharmaceuticals, but concentrating on infectious and liver diseases.
AI Analysis | Feedback
- Hepatitis C Virus (HCV) Drug Components: Compounds like glecaprevir and paritaprevir, discovered by Enanta and licensed to AbbVie, are key components in approved multi-drug regimens for treating chronic HCV infection.
- EDP-938: An investigational N-protein inhibitor currently in Phase 2b clinical trials for the treatment of Respiratory Syncytial Virus (RSV) infection.
- EDP-305: An investigational farnesoid X receptor (FXR) agonist that has completed Phase 2 clinical trials for the treatment of Nonalcoholic Steatohepatitis (NASH).
- Hepatitis B Virus (HBV) Program: A portfolio of investigational nucleoside reverse transcriptase inhibitors (NRTIs), including EDP-514 and EDP-721, in clinical development for treating chronic HBV infection.
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) primarily generates its revenue through collaboration and licensing agreements with other pharmaceutical companies, rather than selling directly to individuals.
Its major customer is:
- AbbVie Inc. (ABBV)
AI Analysis | Feedback
nullAI Analysis | Feedback
Jay R. Luly, Ph.D., President, Chief Executive Officer and DirectorDr. Luly has led Enanta Pharmaceuticals since July 2003, guiding the company through its venture-financed years and a successful IPO in 2013. Under his leadership, Enanta collaborated with AbbVie to discover and develop hepatitis C virus protease inhibitors, glecaprevir and paritaprevir, which are components of MAVYRET® and VIEKIRA PAK® regimens. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. He also held senior leadership positions at Millennium Pharmaceuticals, following its acquisition of LeukoSite, Inc. in 1999, where he had served as Senior Vice President, Drug Discovery and Preclinical Development. From 1983 to 1997, he held several senior drug discovery roles at Abbott Laboratories.
Paul J. Mellett, Chief Financial Officer, Senior Vice President of Finance & Administration
Mr. Mellett joined Enanta in September 2003. Before his tenure at Enanta, he served as Senior Vice President and Chief Financial Officer of Essential Therapeutics from April 2001 to August 2003.
Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
Dr. Kieffer joined Enanta in December 2020. Her previous experience includes various roles of increasing responsibility at Vertex Pharmaceuticals, most recently as Vice President, External Innovation, Business Development, where she evaluated external innovation and led in-licensing and acquisition opportunities. She also held the position of Vice President, Integrated Program Management at Vertex. Earlier in her career at Vertex, she was Director, Clinical Biomarkers and Head of Clinical Virology, leading a team focused on antiviral drug resistance research for Hepatitis C and influenza viruses.
Brendan Luu, Chief Business Officer
Mr. Luu joined Enanta in January 2021. Prior to Enanta, he held several roles at Merck KGaA, including Vice President and Global Head of Oncology Business Development, where he was responsible for business development strategy and executing major transactions across drug development stages. He also worked in regional business development at Merck KGaA. His early career involved engineering, sales, and marketing roles in the chemicals industry with BASF Corporation and in telecommunications with Tyco International.
Scott T. Rottinghaus, Chief Medical Officer
Dr. Rottinghaus joined Enanta in August 2022. He brings over 20 years of clinical experience in drug development across various therapeutic areas such as rare disease, hematology, nephrology, neurology, dermatology, rheumatology, and infectious diseases. Before Enanta, Dr. Rottinghaus served as Vice President and Head of Clinical Development for Hematology and Nephrology at Alexion, AstraZeneca Rare Disease, leading the development of several clinical assets.
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) faces several key risks to its business, primarily stemming from the inherent uncertainties of drug development, ongoing intellectual property disputes, and a highly competitive market.- Clinical Development and Regulatory Risks: The most significant risk for Enanta Pharmaceuticals is the successful clinical development and regulatory approval of its drug candidates. The company's lead respiratory syncytial virus (RSV) candidate, zelicapavir, recently missed its primary endpoint in a Phase 2b study in high-risk adults, leading to a notable drop in stock value. While secondary endpoints were met, there is no guarantee that the FDA will accept alternative endpoints for future registrational studies. Additionally, Enanta is strategically shifting its focus towards immunology, an area where it has less established expertise and faces a "long and uncertain path to market" for its early-stage candidates like EPS-1421 and the STAT6 inhibitor program. Setbacks in clinical trials or delays in development could severely impact investor confidence and the company's valuation. The company also cites general "discovery and development risks" and a "lack of clinical development experience" as important factors that may affect actual results.
- Intellectual Property Litigation: Enanta is engaged in significant and ongoing patent litigation against Pfizer concerning coronavirus protease inhibitors. A US District Court ruling invalidated Enanta's claims regarding a specific patent, a decision the company is appealing. Enanta has also initiated similar litigation in the European Union. These legal proceedings can be costly, time-consuming, and divert management's attention, potentially impacting the company's cash flows, operational strategies, and reputation. Unfavorable outcomes in these cases could hinder Enanta's ability to protect and monetize its intellectual property.
- Competition: Enanta operates in a highly competitive pharmaceutical landscape. The company faces substantial competition from established pharmaceutical companies and other biotechnology firms, particularly in the RSV space where numerous large companies are advancing their own candidates. The development, regulatory, and marketing efforts of competitors regarding vaccines and competitive treatments for RSV could significantly impact Enanta's potential market share and commercial success if its products reach approval.
AI Analysis | Feedback
The following are clear emerging threats to Enanta Pharmaceuticals (ENTA):
-
RSV Market Contraction Due to Preventative Therapies: The recent FDA approvals and commercialization (2023-2024) of multiple highly effective preventative therapies for Respiratory Syncytial Virus (RSV), including Pfizer's Abrysvo (vaccine), Sanofi/AstraZeneca's Beyfortus (nirsevimab, monoclonal antibody), and Moderna's mRNA-1345 (vaccine), pose a significant emerging threat. While Enanta's lead RSV candidate, EDP-938, is an antiviral treatment, widespread adoption of these preventative options could substantially reduce the overall incidence of RSV and, consequently, shrink the market for RSV treatment drugs, thereby impacting the commercial potential of EDP-938.
-
NASH Market Competition and First-Mover Advantage: The FDA approval of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) in March 2024 as the first-ever drug for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) establishes a significant first-mover advantage and market leader. This creates a challenging competitive landscape for Enanta's earlier-stage MASH pipeline programs (e.g., EDP-766 in Phase 1), which must now compete against an approved, commercially available product. This significantly raises the bar for market entry and potential market share for Enanta's MASH candidates, especially after a prior Phase 2 failure with EDP-305.
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) is focused on developing small molecule drugs primarily in virology and immunology. Their main product candidates in development are for Respiratory Syncytial Virus (RSV) and Hepatitis B Virus (HBV). While not a current primary focus, they have also previously developed clinical candidates in Nonalcoholic Steatohepatitis (NASH).
Respiratory Syncytial Virus (RSV) Treatments
Enanta's lead candidates for RSV are zelicapavir (EDP-938) and EDP-323, both oral inhibitors.
- The global respiratory syncytial virus treatment market was valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033, growing at a Compound Annual Growth Rate (CAGR) of 14.9%.
- Another estimate indicates the global RSV therapeutics market size was USD 1.6 billion in 2024 and is expected to reach USD 4.0 billion by 2031, growing at a CAGR of 14.5% from 2025-2031.
- In 2019, the global respiratory syncytial virus therapeutics market size stood at USD 1,111.3 million and was projected to grow to USD 4,003.4 million by 2027, with a CAGR of 30.9% from 2020–2027.
- The North American market for RSV therapeutics was valued at USD 396.0 million in 2019.
Hepatitis B Virus (HBV) Treatments
Enanta has EDP-514, an HBV core antigen inhibitor, in its pipeline for the treatment of chronic hepatitis B.
- The global market for hepatitis B treatments is projected to increase from USD 1.6 billion in 2022 to USD 10.5 billion in 2029, at a CAGR of 30%.
- The global chronic hepatitis B market size reached USD 2,709.4 million in 2023 and is expected to reach USD 3,379.3 million by 2034, exhibiting a CAGR of 2.03% during 2024-2034.
- Another report estimated the global chronic hepatitis B (CHB) market was valued at USD 4.6 billion in 2021 and is projected to reach USD 6.2 billion by 2031, growing at a CAGR of 3% from 2022 to 2031.
Nonalcoholic Steatohepatitis (NASH) Treatments
Enanta has developed clinical candidates in NASH, such as EDP-305.
- The global Nonalcoholic Steatohepatitis (NASH) market size is estimated at USD 9980.53 million in 2024 and is expected to reach USD 314068.7 million by 2033, with a 46.7% CAGR.
- The global Nonalcoholic Steatohepatitis Treatment Market size was USD 5.5 billion in 2023 and is expected to grow at a CAGR of 29.9% from 2024 to 2032, reaching USD 57.9 billion by 2032.
- The North America non-alcoholic steatohepatitis treatment market is expected to grow at a 28.4% CAGR, to reach USD 23.2 billion by 2032.
- In 2024, North America dominated the global non-alcoholic steatohepatitis treatment market share by 79%.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Enanta Pharmaceuticals (ENTA) over the next 2-3 years:1. Advancement and Potential Commercialization of RSV Treatments: Enanta Pharmaceuticals is heavily focused on its Respiratory Syncytial Virus (RSV) portfolio, with zelicapavir and EDP-323 as its leading oral antiviral candidates. The company successfully met target enrollment for RSVHR, a Phase 2 study of zelicapavir in high-risk adults, and is on track to report topline data in late Q3 2025. Positive Phase 2b results for zelicapavir in high-risk adults were announced in late September 2025, indicating faster symptom resolution and a lower hospitalization rate, which provides support for advancing zelicapavir into Phase 3 development. Enanta possesses the most comprehensive RSV antiviral portfolio in development with two differentiated mechanisms of action (N- and L-protein inhibition) and is evaluating potential partnership opportunities to bring these therapeutics to patients.
2. Progression and Potential Launch of Immunology Pipeline Products: Enanta is actively advancing its immunology pipeline. The company is developing a KIT inhibitor treatment for chronic spontaneous urticaria (CSU), with a candidate selection for EPS-1421 expected in the fourth quarter of fiscal 2024. Additionally, a STAT6 inhibitor program is progressing, with plans to select a development candidate in the second half of 2025. This STAT6 inhibitor program is initially targeting atopic dermatitis with potential for expansion into asthma and other inflammatory diseases. Enanta also plans to introduce a third immunology program in 2025, further diversifying its potential revenue streams from new product introductions.
3. Ongoing Royalty Revenue from MAVYRET/MAVIRET: Enanta continues to generate royalty revenue from AbbVie's global net sales of MAVYRET®/MAVIRET®, a treatment for chronic hepatitis C virus (HCV) infection. While a portion (54.5%) of these royalties is currently paid to OMERS under a royalty sale transaction until June 30, 2032 (subject to a cap), the remaining and eventual full retention of these royalties contributes to Enanta's financial stability and ongoing funding for its development programs. This established revenue stream provides a base, and the increasing retained portion over time could represent a growth driver as the liability is amortized.
4. Strategic Partnerships for RSV Program Development: Enanta is exploring potential partnership opportunities to strategically and capital-efficiently advance its RSV program. A successful partnership for zelicapavir and/or EDP-323 could lead to significant upfront payments, milestone achievements, and shared commercialization revenue, thereby boosting future revenue growth and accelerating the path to market for these promising candidates.
AI Analysis | Feedback
Share Issuance
- In October 2025, Enanta Pharmaceuticals completed an upsized public offering of 7,475,000 shares of its common stock at $10.00 per share.
- This offering generated gross proceeds of $74.75 million.
- The net proceeds are intended to fund clinical trials, research and development efforts, working capital, and other general corporate purposes.
Inbound Investments
- In April 2023, Enanta sold 54.5% of its ongoing MAVYRET®/MAVIRET® royalties from AbbVie to OMERS, a Canadian pension plan, for an upfront payment of $200 million.
- Enanta retains 45.5% of all royalties until a 1.42x cap on aggregate payments to OMERS is reached, after which 100% of all further royalties revert to Enanta.
Capital Expenditures
- For the fiscal year ended September 30, 2023, Enanta spent approximately $6.3 million in capital expenditures primarily for additional space and tenant improvements.
- The company received a tenant improvement allowance of $2.5 million from the landlord in fiscal year 2023.
- As of June 2025, quarterly capital expenditures were reported as $155,000.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Enanta Pharmaceuticals Earnings Notes | 12/16/2025 | |
| Can Enanta Pharmaceuticals Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 43.09 |
| Mkt Cap | 5.6 |
| Rev LTM | 447 |
| Op Inc LTM | -58 |
| FCF LTM | -39 |
| FCF 3Y Avg | -170 |
| CFO LTM | -32 |
| CFO 3Y Avg | -107 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.6% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 3.0% |
| QoQ Delta Rev Chg LTM | 0.8% |
| Op Mgn LTM | -79.7% |
| Op Mgn 3Y Avg | -369.4% |
| QoQ Delta Op Mgn LTM | 24.7% |
| CFO/Rev LTM | -27.5% |
| CFO/Rev 3Y Avg | -339.4% |
| FCF/Rev LTM | -40.6% |
| FCF/Rev 3Y Avg | -350.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.6 |
| P/S | 12.9 |
| P/EBIT | -2.8 |
| P/E | -11.7 |
| P/CFO | -8.5 |
| Total Yield | -3.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -11.9% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.0% |
| 3M Rtn | 19.9% |
| 6M Rtn | 68.5% |
| 12M Rtn | 104.6% |
| 3Y Rtn | 69.6% |
| 1M Excs Rtn | 5.6% |
| 3M Excs Rtn | 19.2% |
| 6M Excs Rtn | 57.6% |
| 12M Excs Rtn | 85.5% |
| 3Y Excs Rtn | -2.0% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing small molecule drugs, with an emphasis on treatments for viral infections | 68 | 79 | |||
| License revenue | 0 | ||||
| Royalty revenue | 86 | 97 | 122 | ||
| Total | 68 | 79 | 86 | 97 | 122 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing small molecule drugs, with an emphasis on treatments for viral infections | -122 | ||||
| Total | -122 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing small molecule drugs, with an emphasis on treatments for viral infections | -116 | ||||
| Total | -116 |
Price Behavior
Price Behavior
| Market Price | $13.19 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 03/21/2013 | |
| Distance from 52W High | -21.7% | |
| 50 Days | 200 Days | |
| DMA Price | $13.99 | $9.59 |
| DMA Trend | up | up |
| Distance from DMA | -5.7% | 37.5% |
| 3M | 1YR | |
| Volatility | 50.8% | 117.8% |
| Downside Capture | 18.93 | 87.78 |
| Upside Capture | 130.97 | 171.61 |
| Correlation (SPY) | 21.2% | 14.9% |
ENTA Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.86 | 0.21 | 0.94 | 1.07 | 0.90 | 1.01 |
| Up Beta | 1.92 | 1.93 | 3.58 | 0.37 | 0.13 | 0.50 |
| Down Beta | -0.64 | -0.27 | 0.10 | 0.33 | 1.22 | 1.14 |
| Up Capture | -324% | -36% | 114% | 231% | 266% | 52% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 18 | 30 | 61 | 124 | 337 |
| Down Capture | 37% | 70% | 20% | 54% | 95% | 110% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 22 | 29 | 61 | 120 | 407 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENTA | |
|---|---|---|---|---|
| ENTA | 168.4% | 117.5% | 1.26 | - |
| Sector ETF (XLV) | 7.1% | 17.2% | 0.24 | 13.9% |
| Equity (SPY) | 16.0% | 19.2% | 0.64 | 14.7% |
| Gold (GLD) | 66.9% | 23.7% | 2.11 | 4.2% |
| Commodities (DBC) | 7.0% | 16.3% | 0.23 | 4.0% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 11.3% |
| Bitcoin (BTCUSD) | -19.7% | 39.9% | -0.46 | 15.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENTA | |
|---|---|---|---|---|
| ENTA | -22.4% | 72.9% | -0.07 | - |
| Sector ETF (XLV) | 7.3% | 14.5% | 0.33 | 22.6% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 22.5% |
| Gold (GLD) | 19.9% | 16.6% | 0.97 | 8.0% |
| Commodities (DBC) | 11.4% | 18.9% | 0.49 | 3.4% |
| Real Estate (VNQ) | 4.5% | 18.8% | 0.15 | 21.5% |
| Bitcoin (BTCUSD) | 20.9% | 57.6% | 0.56 | 12.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENTA | |
|---|---|---|---|---|
| ENTA | -7.3% | 60.8% | 0.11 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 30.1% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 29.4% |
| Gold (GLD) | 15.0% | 15.3% | 0.81 | 3.9% |
| Commodities (DBC) | 8.3% | 17.6% | 0.39 | 9.1% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 24.2% |
| Bitcoin (BTCUSD) | 71.1% | 66.4% | 1.10 | 9.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/17/2025 | -3.6% | 6.5% | 13.3% |
| 8/11/2025 | 5.7% | 25.9% | 28.4% |
| 5/12/2025 | -5.8% | 7.4% | 43.2% |
| 2/10/2025 | 14.1% | 52.9% | 48.4% |
| 11/25/2024 | -5.0% | -2.8% | -33.4% |
| 8/5/2024 | 1.2% | -4.0% | -5.5% |
| 5/6/2024 | -10.3% | -11.6% | -15.1% |
| 2/7/2024 | 0.8% | 7.7% | 25.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 10 |
| # Negative | 16 | 16 | 14 |
| Median Positive | 6.1% | 8.2% | 19.0% |
| Median Negative | -3.6% | -5.7% | -9.4% |
| Max Positive | 15.1% | 52.9% | 48.4% |
| Max Negative | -25.7% | -24.6% | -37.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/19/2025 | 10-K |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 11/27/2024 | 10-K |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/22/2023 | 10-K |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/08/2023 | 10-Q |
| 09/30/2022 | 11/23/2022 | 10-K |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/10/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capps, Kathleen S | See Remarks | Direct | Sell | 12052025 | 14.23 | 323 | 4,596 | 119,205 | Form |
| 2 | Trout, Harry R Iii | See Remarks | Direct | Sell | 12052025 | 14.23 | 542 | 7,713 | 232,632 | Form |
| 3 | Rottinghaus, Scott T | Chief Medical Officer | Direct | Sell | 12052025 | 14.23 | 798 | 11,356 | 310,100 | Form |
| 4 | Luu, Brendan | Chief Business Officer | Direct | Sell | 12052025 | 14.23 | 1,394 | 19,837 | 545,422 | Form |
| 5 | Kieffer, Tara Lynn | Chief Product Strategy Officer | Direct | Sell | 12052025 | 14.23 | 2,106 | 29,968 | 435,723 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.